Proven Solutions ImprovedSM
Tosk is developing a family of inexpensive, small molecule drugs — what we call CompanionTM drugs — that when administered alongside certain cancer therapies such as methotrexate, doxorubicin, cisplatin, EGFR inhibitors and radiation — what we call parent therapies — will significantly improve patient outcomes, enhance dosing regimens and cut the cost of treating both cancer and toxic side effects that might occur.
Tosk has patented two new pharmaceutical products and has two other preclinical-stage products in development.
TK-90: Our most advanced, patented drug — now in human clinical trials — is targeted at mucositis side effect reduction. Mucositis is the painful inflammation and ulceration of the mucous membranes lining the mouth, throat, and digestive tract, usually as an adverse effect of chemotherapy or radiation. Mucositis is costly to treat and may result in affecting or even terminating optimum treatment. Oral mucositis, inflammation and ulceration that occurs in the mouth, is a common and often debilitating complication of cancer treatment. Mucositis in the gut can introduce a route of infection that can be debilitating and potentially fatal.
There were 1.7 million new cases of cancer and 600,000 cancer-related deaths in the U. S. last year. This is despite regular media reports of breakthroughs in treatment, such as monoclonal antibodies and immunotherapies, and many billions of dollars spent on cancer research. New approaches may have long-term promise, but the reality is, most cancers are still treated with drugs that are decades old.
Tosk uses two proprietary drug discovery methods to identify potential CompanionTM drugs. Together, we call these methods OMDSM for Optimizing Marketed DrugsSM because they allow us to efficiently screen compounds for their potential to block the adverse side effects of prescription drugs, or make certain drugs effective in patients who currently do not benefit from therapy.
Brian D. Frenzel, President and CEO
Mr. Frenzel has over 25 years experience as a biomedical company executive, including serving as CEO of Centaur Pharmaceuticals, CEO of Adeza Biomedical, CEO of Vesta Medical, and COO of Genelabs Technologies. Previously, Mr. Frenzel was director of corporate planning at Syntex Corporation, a principal at Booz, Allen & Hamilton, a consultant at the Boston Consulting Group, and a lieutenant in the United States Navy Nuclear Power Program. Mr. Frenzel holds a BS in physics and an MBA from Stanford University.